Population Pharmacokinetics and Exposure Response Assessment of CC‐292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia

CC‐292, a potent Bruton tyrosine kinase inhibitor, is under development for the treatment of B‐cell malignancies. An analysis was performed to develop a population pharmacokinetic model of CC‐292 and assess the influence of demographics and disease‐related covariates on CC‐292 exposure and to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Ramírez‐Valle, Francisco, Xue, Yongjun, Ventura, Judith I., Gouedard, Olivier, Mei, Jay, Takeshita, Kenichi, Palmisano, Maria, Zhou, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599992/
https://www.ncbi.nlm.nih.gov/pubmed/28543084
http://dx.doi.org/10.1002/jcph.923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599992/
https://www.ncbi.nlm.nih.gov/pubmed/28543084
http://dx.doi.org/10.1002/jcph.923

Ejemplares similares